Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): Study protocol for a phase II/III, multicenter, randomized, open-label clinical trial

Myungsun Lee, Jeongha Mok, Deog Kyeom Kim, Tae Sun Shim, Won Jung Koh, Doosoo Jeon, Taehoon Lee, Seung Heon Lee, Ju Sang Kim, Jae Seuk Park, Ji Yeon Lee, Song Yee Kim, Jae Ho Lee, Kyung Wook Jo, Byung Woo Jhun, Young Ae Kang, Joong Hyun Ahn, Chang Ki Kim, Soyoun Shin, Taeksun SongSung Jae Shin, Young Ran Kim, Heejung Ahn, Seokyung Hahn, Ho Jeong Won, Ji Yeon Jang, Sang Nae Cho, Jae Joon Yim

    Research output: Contribution to journal › Article › peer-review

    5 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): Study protocol for a phase II/III, multicenter, randomized, open-label clinical trial'. Together they form a unique fingerprint.

    Medicine & Life Sciences